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Abstract
Background Different prediction models for operative mortality after esophagectomy have been developed. The aim of this
study is to independently validate prediction models from Philadelphia, Rotterdam, Munich, and the ASA.
Methods The scores were validated using logistic regression models in two cohorts of patients undergoing esophagectomy
for cancer from Switzerland (n=170) and Australia (n=176).
Results All scores except ASA were significantly higher in the Australian cohort. There was no significant difference in
30-day mortality or in-hospital death between groups. The Philadelphia and Rotterdam scores had a significant
predictive value for 30-day mortality (p=0.001) and in-hospital death (p=0.003) in the pooled cohort, but only the
Philadelphia score had a significant prediction value for 30-day mortality in both cohorts. Neither score showed any
predictive value for in-hospital death in Australians but were highly significant in the Swiss cohort. ASA showed only a
significant predictive value for 30-day mortality in the Swiss. For in-hospital death, ASA was a significant predictor in
the pooled and Swiss cohorts. The Munich score did not have any significant predictive value whatsoever.
Conclusion None of the scores can be applied generally. A better overall predictive score or specific prediction scores for
each country should be developed.
Keywords Risk prediction models . Esophagectomy .
In-hospital death . 30-day mortality
Introduction
Surgical resection is the cornerstone of curative treatment for
esophageal cancer. Despite advances in surgical, anesthetic,
and intensive care techniques, hospital mortality is still
substantial, with rates reported to be up to 14%.1 Different
approaches to decrease the perioperative morbidity and
mortality have been used, such as the introduction of
minimally invasive surgical techniques, thoracic epidural
analgesia, standardized perioperative pathways, and preop-
erative selection of patients.2,3 As esophageal cancer usually
occurs in the elderly population and many of these individuals
have significant comorbidities, careful preoperative assess-
ment of fitness and subsequent selection of appropriate
surgical candidates are important steps which can improve
short-term outcomes for individuals undergoing this surgery.
J Gastrointest Surg (2009) 13:611–618
DOI 10.1007/s11605-008-0761-y
No score generally applicable
U. Zingg (*) : C. Langton : B. Addison : B. P. L. Wijnhoven :
D. I. Watson
Flinders University Department of Surgery,
Flinders Medical Center,
Flinders Drive, Bedford Park,
Adelaide 5042 South Australia, Australia
e-mail: uzingg@uhbs.ch
U. Zingg : J. Forberger
Department of Surgery, Triemli Hospital,
Zurich, Switzerland
B. P. L. Wijnhoven
Department of Surgery, Erasmus Medical Center,
Rotterdam, The Netherlands
S. K. Thompson
Discipline of Surgery, University of Adelaide,
Adelaide, South Australia, Australia
A. J. Esterman
School of Nursing and Midwifery, University of South Australia,
Adelaide, South Australia, Australia
A number of studies have investigated risk factors for in-
hospital mortality following esophagectomy. Age, comor-
bidity, and pulmonary status have been identified as
independent risk factors.4,5 Hospital volume has also been
shown to significantly influence mortality rates, with 50%
lower rates in high-volume centers.6 Several risk prediction
models have been developed, but only a minority of them
have been validated in independent cohorts.
The Physiological and Operative Severity Score for the
Enumeration of Mortality and Morbidity (POSSUM) has
been adjusted to accurately predict death from gastric and
esophageal surgery (O-POSSUM).7 Three subsequent
studies evaluated the O-POSSUM and showed a poor
goodness of fit of the model and substantial overprediction
of postoperative death using independent patient cohorts
worldwide.8–10
Other more simplified and practical prediction models
have been proposed. Steyerberg et al.11 from Rotterdam,
the Netherlands, developed a simple score which included
age, comorbidity, hospital volume, and whether the patient
received neoadjuvant treatment. Very similar, but without
using neoadjuvant treatment a as variable, is the recently
described prediction model of Ra et al.12 from Philadelphia.
Siewert’s group13 in Munich proposed a score based on
pulmonary, hepatic, and cardiac function as well as on
general status. The American Society of Anesthesiologists
(ASA) score has also been shown to be a reliable predictor
of mortality.14 All of these models accurately predicted
postoperative hospital death in the initial validation
studies. However, to our knowledge, these models have
not been validated in independent cohorts of esophageal
cancer patients. Hence, the aim of our study was to
investigate the prognostic value of these four prediction
models (Rotterdam, Philadelphia, Munich, ASA; Table 1)
in two geographically different cohorts, as well as in a
pooled cohort of patients undergoing esophagectomy for
cancer.
Patients and Methods
Two cohorts of patients undergoing esophagectomy for
cancer from Switzerland and Australia were used to assess
the validity of four different prediction models. The Swiss
cohort of patients consisted of a consecutive series of 170
patients who underwent esophagectomy at one large
teaching hospital in Zurich from 1990 to 2007. The
Australian cohort consisted of a consecutive series of 176
patients operated in Adelaide, South Australia between
1999 and 2007 at two university hospitals and two private
hospitals. All patients underwent surgery using a transtho-
racic approach, and in all patients the stomach was used as
conduit for reconstruction. The anastomosis was either
performed with a stapled technique or hand-sewn, accord-
ing to the individual surgeon’s preference. In both
countries, patients with advanced tumors (T3 or N+)
usually received neoadjuvant treatment. This usually
entailed two cycles of 5-fluorouracil and cisplatin in
combination with 45 to 50 Gy of radiotherapy. Surgery
was performed 4 to 8 weeks after the completion of any
pretreatment.
For both cohorts, data (demographics, comorbidity,
tumor stage, morbidity, mortality) were retrospectively
retrieved from the case notes for patients undergoing
surgery between 1990 and 1998. From 1999 onwards, data
were prospectively retrieved and stored in databases in both
sites. Both 30-day mortality and in-hospital mortality
outcomes were determined.
For all individual patients, the Rotterdam, Philadelphia,
and ASA scores were calculated, and no data were
missing. The Munich score includes an aminopyrine
breath test to classify hepatic function as either normal,
compromised, or severely compromised. As this test was
not performed in either the Swiss or the Australian cohort,
hepatic status was assessed using routine clinical data such
as liver function tests (alanine aminotransferase, ALT,
aspartate aminotransferase, AST, gamma-glutamyl trans-
ferase, GGT) in preoperative blood samples as well as
radiological findings. ALT was considered to be patho-
logic if serum levels exceeded 50 iU/l, AST if more than
40 iU/l, and GGT if more than 60 iU/l. Routine imaging
with computed tomography was performed for all patients.
Evidence of liver cirrhosis or portal hypertension was also
noted. Patients were classified as having normal hepatic
function when neither blood tests nor imaging showed any
evidence of liver disease. If liver function tests were
elevated or imaging showed evidence of mild cirrhosis
without portal hypertension, hepatic function was consid-
ered to be compromised. No patients with severe cirrhosis
or portal hypertension underwent esophagectomy in either
of these cohorts.
Additionally, the Munich score uses the Karnofsky index
to assess the general status of the patient. This index was
not initially part of the prospective databases, and hence for
this aspect the general physical status was assessed
retrospectively using the clinical notes. Theses results were
then adapted to the Karnofsky score. Obesity was defined
as a body mass index (BMI) above 30 kg/m2.
The study was approved by the responsible clinical
research ethics committees in the two countries.
Statistical Analysis
Comparison of demographic and clinical data between the
two patient cohorts (Swiss and Australia) was undertaken
using Chi-squared tests for categorical data and Student’s t
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tests or Mann–Whitney U tests for continuous data. Since
all four prediction scores were skewed, correlation between
them was assessed by Spearman rank correlation. Logistic
regression was used to calculate whether each score could
predict 30-day mortality, in-hospital mortality, or prolonged
ventilation. The latter was used as a marker of severe
morbidity. Prolonged ventilation was defined as ventilation
required for more than 72 h.
Models were developed for each of the three-outcome
and four-risk-score combinations, i.e., 12 models in
total. For each combination, the initial model included
the score, country, and score–country interaction term. If
the latter was statistically significant, separate models
were developed for each country collection with no
attempt to pool the data across the two countries. The
Hosmer and Lemeshow test was performed to evaluate
Table 1 The Four Validated Prediction Scores
Variable Definition of variable Points
Rotterdam score 11
Age (years) 50 −1
65 0
80 1
Comorbidity Pulmonary 1
Cardiovascular 1
Diabetes 1
Hepatic 1
Renal 1
Neoadjuvant therapy Radiotherapy 1.5
Chemoradiotherapy 1
Hospital volume Low (≤1) 0
Intermediate (1.1-2.5) −0.5
High (≥2.6) −1.5
Very high (≥50) −2
Philadelphia score 12
Age 65−69 0
70−79 1
80+ 2
Hospital volume High 0
Medium 2
Low 2
Charlson score 0 0
1 0
≥2 2
Munich score 13
Pulmonary function (weighting factor 2) Normal (vital capacity >90% and PaO2 >70 mmHg) 1
Compromised (vital capacity <90% or PaO2 <70 mmHg) 2
Severely compromised (vital capacity <90% and PaO2 <70 mmHg) 3
Hepatic function (weighting factor 2) Normal (aminopyrine breath test >0.4) 1
Compromised (aminopyrine breath test <0.4, no cirrhosis) 2
Severely compromised (cirrhosis) 3
Cardiac function based on cardiologists impression
(weighting factor 3)
Normal (normal risk for major surgery) 1
Compromised (increased risk for major surgery) 2
Severely compromised (high risk for major surgery) 3
General status (weighting factor 4) Normal (Karnofsky index >80% and good cooperation) 1
Compromised (Karnofsky index ≤80% or poor cooperation) 2
Severely impaired (Karnofsky index ≤80% and poor cooperation) 3
American Society of Anesthesiologists (ASA) score 14
Normal healthy patient 1
Patient with mild systemic disease 2
Patient with severe systemic disease 3
Patient with severe systemic disease that is a constant threat to life 4
Moribund patient who is not expected to survive without the operation 5
Declared brain-dead patient whose organs are removed for donor purposes 6
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the goodness of fit of each logistic regression model.
Nagelkerke’s R-squared test was used to determine the
percentage of variability in outcome explained by the
model.
Statistical significance for each model was set at
p<0.05. Statistical analyses were performed with SPSS®
version 16 for Windows. For all outcomes, a logistic
regression of a binary response variable (Y) on a
continuous normally distributed variable (X) with a sample
size of 289 observations for in-hospital death, 425
observations for 30-day mortality, and 154 observations
for prolonged ventilation achieved 80% power at a 0.05
significance level. This detected a change in probability
(Y=1) from the value of 0.060 (6% mortality) at the mean
of X to 0.113 when X is increased to one standard
deviation above the mean. This change corresponds to an
odds ratio of 2.000.
Results
The pooled cohort included 346 patients. The two cohorts
from Switzerland (n=170) and Australia (n=176) did not
differ in age or the percentage of obese patients. There
were, however, significant differences in some other patient
or tumor characteristics, as shown in Table 2. All scores
were significantly different between the cohorts, with the
Australian cohort having higher scores except for ASA
(Table 3). There were no significant differences in 30-day
mortality, in-hospital death, or the frequency of prolonged
ventilation between groups (Table 4). There was a good
correlation between the Philadelphia and Rotterdam scores,
whereas no correlation to or in between the other scores
was detected (Table 5).
Pooling was allowed in all scores and outcomes (Table 6).
The Philadelphia and Rotterdam scores had a significant
predictive value for 30-day mortality and in-hospital death in
the pooled cohort. After stratifying into the two countries,
only the Philadelphia score had a significant prediction value
for 30-day mortality in both cohorts. The Rotterdam score
had no significant predictive value for 30-day mortality in
Australians and neither score showed any predictive value
for in-hospital death in Australians. Both scores were highly
significant in the Swiss cohort.
The Munich score did not have any significant predictive
value for operative mortality in the pooled data or in any of
the cohorts. ASA showed only a significant predictive
value for 30-day mortality in the Swiss but not in the
pooled or Australian cohorts. For in-hospital death, ASA
was a significant predictor in the pooled and Swiss cohorts.
Concerning prediction of prolonged ventilation as an
indicator for severe morbidity, the Munich score had a
significant predictive value in the Australians but neither in
the pooled or Swiss cohorts. ASA predicted prolonged
hospitalization only in the pooled cohort but not in the
country subgroups.
Table 2 Basic Descriptives Between the Swiss and Australian
Cohorts
Australians Swiss p value
N=176 N=170
Age (SEM) 62.2 (0.7) 62.5 (0.8) 0.814a
Sex Male 137 (77.8%) 147 (86.5%) 0.036b
Female 39 (22.2%) 23 (13.5%)
Comorbidity Yes 110 (62.5%) 76 (44.7%) 0.001b
No 65 (37.5%) 94 (55.3%)
Obesity Yes 30 (17.0%) 20 (11.8%) 0.163b
No 146 (83.0%) 150 (88.2%)
Neoadjuvant
treatment
Yes 96 (54.5%) 44 (25.9%) <0.001b
No 80 (45.5%) 126 (74.1%)
Type Adeno 134 (76.1%) 125 (73.5%) 0.010b
SCC 29 (16.5%) 42 (24.7%)
Other 13 (7.4%) 3 (1.8%)
SEM standard error of mean
a Students t test
b Chi-squared test
Table 3 Results of the Four Scores in the Two Different Cohorts
Philadelphia score Rotterdam score Munich score ASA score
Australians (n=176) Median 1.00 −0.205 11.0 2.0
Mean rank 184.3 187.3 187.7 162.0
Minimum 0 −2.5 4 1
Maximum 5 3.0 16 3
Swiss (n=170) Median 1.00 −0.500 11.0 2.0
Mean rank 162.4 158.8 158.8 185.4
Minimum 0 −2.5 6 1
Maximum 4 2.5 16 3
p valuea 0.030 0.008 0.003 0.012
ASA American Society of Anesthesiologists
aMonte Carlo Exact Mann–Whitney U test
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Discussion
Analysis of the pooled data in this study demonstrated that
two of the risk prediction scores, Philadelphia and
Rotterdam, correlated with operative mortality following
esophagectomy in this group of esophageal cancer patients.
The predictive value was highly significant for the Swiss
population, whereas the scores were only marginally or not
significant in the Australian cohort. The ASA score only
predicted operative mortality for the Swiss cohort but not
for the Australian cohort. The Munich score had no
significant predictive value in either patient cohort.
The Rotterdam score and the Munich score were
developed using logistic regression analysis in a primary
cohort and then validation in other cohorts. Both scores
showed good agreement between the predicted risks and
the observed risks.11,13 The Philadelphia and ASA scores
were developed again with logistic regression, but these
scores were not validated with other cohorts. Both models
accurately predicted postoperative mortality in initial
reports.12,14 The time period over which the patients
were collected was long for three of the scores (22 years in
the Rotterdam score, 14 years in the Munich score, and
15 years in the ASA score), whereas the data for the
validation of the Philadelphia score were collected over a
6-year period.
There were some significant differences between the two
cohorts of patients we analyzed in our study and this might
explain some of our findings. The Australian cohort had
higher Philadelphia, Rotterdam, and Munich scores but a
lower ASA score. The Rotterdam score includes comor-
bidity and neoadjuvant treatment, both of which were more
prevalent in the Australian cohort, thus explaining the
higher scores. The higher Munich score can be again
explained by the more frequent comorbidity seen in the
Australian cohort. The significant difference in ASA scores
is related to the number of patients with ASA score of 1
(Australia 38 vs. Switzerland 11). The reason for this
difference is unclear. A possible explanation is that the
ASA score is defined by the individual anesthetist, and this
might be influenced by differences in clinical assessment.
The Munich score in this study was not done with an
aminopyrine breath test. However, we did assess the hepatic
function by other means, and it was not difficult to classify
patients as having either a normal or compromised liver
function. Furthermore, no patients with significant liver
disease underwent surgery in either country. It is therefore
likely that all patients were adequately assessed for this
criterion.
Concerning prolonged ventilation as a marker of severe
morbidity, the ASA score was a significant predictor in the
pooled cohort, and the Munich score was also predictive in
the Australian cohort. However, cautious interpretation of
these results is necessary as all scores were primarily
developed to predict hospital mortality. The prediction of
morbidity with the ASA score as demonstrated by Sauvanet
et al.14 is only reproduced in our pooled cohort not in the
subcohorts. This might indicate that a large number of
patients are necessary to reach statistical significance, and
for this reason the true prediction value was not established
in the individual cohorts. Sauvanet et al. evaluated the ASA
score in a group of over 1,000 patients. There were
sufficient patients in our pooled cohort of patients to ensure
sufficient statistical power of the study for valid assessment
of all other risk assessment tools.
Table 5 Spearman Rank Correlation Between Scores Stratified According to Country
Philadelphia score Rotterdam score Munich score ASA score
Australians (n=176) Philadelphia score 1.000 0.822 0.581 0.345
Rotterdam score 0.822 1.000 0.643 0.399
Munich score 0.581 0.643 1.000 0.483
ASA score 0.345 0.399 0.483 1.000
Swiss (n=170) Philadelphia score 1.000 0.815 0.609 0.264
Rotterdam score 0.815 1.000 0.561 0.277
Munich score 0.609 0.561 1.000 0.379
ASA score 0.264 0.277 0.379 1.000
ASA American Society of Anesthesiologists
Table 4 30-day Mortality, In-Hospital Death, and Incidence of
Prolonged Ventilation in the Two Cohorts
Australians
(n=176)
Swiss
(n=170)
p
valuea
30-day mortality Yes 8 (4.5%) 7 (4.1%) 1.000
No 168 (95.5%) 163 (95.9%)
In-hospital
mortality
Yes 14 (8.0%) 8 (4.7%) 0.272
No 162 (92.0%) 162 (95.3%)
Prolonged
ventilation
Yes 20 (11.4%) 26 (15.3%) 0.344
No 156 (88.6%) 144 (84.7%)
a Chi-squared test
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The female-to-male ratio was different in our two
cohorts. To our knowledge, only one study has identified
sex as an independent predictor of death, with women
having an odds ratio of 1.5 for inpatient death.15 The
majority of studies have not shown any influence of sex
on hospital mortality.1,4,12,16–18 However, a difference in
outcome between histological subtypes has been sug-
gested. The percentage of adenocarcinomas was very
similar in both of our groups. One previous study has
shown a higher operative mortality for patients with
squamous cell cancer, but this has not been supported
by other studies.18,19 Many studies, however, do report
long-term survival differences for different histological
subtypes.18–22
Operative mortality and the frequency of prolonged
ventilation were similar in both cohorts and comparable to
other published series.17,18,23,24 A trend towards higher in-
hospital mortality in the Australian cohort was seen,
whereas 30-day mortality rates were similar. In-hospital
mortality may better reflect general comorbidities, as
Table 6 Results of the Logistic Regression Analyses
Australians (n=176) Swiss (n=170) Pooled (n=346)
30-day mortality
Philadelphia score p value 0.045 0.012 0.001
Hosmer and Lemeshow test 0.825 0.248 0.735
Nagelkerke R-squared 0.068 0.125 0.092
Rotterdam score p value 0.269 0.003 0.003
Hosmer and Lemeshow test 0.608 0.465 0.266
Nagelkerke R-squared 0.022 0.207 0.085
Munich score p value 0.959 0.188 0.431
Hosmer and Lemeshow test 0.345 0.989 0.634
Nagelkerke R-squared <0.001 0.033 0.006
ASA score p value 0.661 0.019 0.065
Hosmer and Lemeshow test 0.601 0.867 0.747
Nagelkerke R-squared 0.004 0.135 0.034
In-hospital death
Philadelphia score p value 0.068 0.004 0.001
Hosmer and Lemeshow test 0.924 0.232 0.784
Nagelkerke R-squared 0.042 0.158 0.082
Rotterdam score p value 0.088 0.002 <0.001
Hosmer and Lemeshow test 0.681 0.688 0.064
Nagelkerke R-squared 0.039 0.224 0.098
Munich score p value 0.611 0.090 0.490
Hosmer and Lemeshow test 0.415 0.958 0.035
Nagelkerke R-squared 0.003 0.050 0.004
ASA score p value 0.271 0.008 0.021
Hosmer and Lemeshow test 0.869 0.880 0.270
Nagelkerke R-squared 0.016 0.163 0.043
Prolonged ventilation
Philadelphia score p value 0.500 0.070 0.095
Hosmer and Lemeshow test 0.304 0.771 0.286
Nagelkerke R-squared 0.005 0.032 0.014
Rotterdam score p value 0.535 0.067 0.105
Hosmer and Lemeshow test 0.965 0.016 0.174
Nagelkerke R-squared 0.004 0.034 0.014
Munich score p value 0.029 0.476 0.060
Hosmer and Lemeshow test 0.083 <0.001 <0.001
Nagelkerke R-squared 0.055 0.005 0.019
ASA score p value 0.060 0.060 0.006
Hosmer and Lemeshow test 0.530 0.323 0.024
Nagelkerke R-squared 0.042 0.037 0.041
p value, goodness-of-fit measure, and percentage of variability in outcome explained by the model for 30-day mortality, in-hospital death, and
prolonged ventilation in the two collections and in the pooled data (where pooling was allowed after testing for country interaction). The first
column shows the score used for prediction. The p value refers to the statistical significance of the regression coefficient. A Hosmer and
Lemeshow statistic of p>0.05 demonstrates a good fit
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patients with surgical complications may die earlier,
whereas pulmonary, cardiac, and renal impairment may
lead to a prolonged postoperative course with slow
deterioration and ultimately death after more than 30 days
of hospitalization.
There was a good correlation between the Philadelphia
and Rotterdam risk scores with a correlation coefficient of
over 0.8. This is not surprising as these models used similar
variables. Interestingly, the Philadelphia score does not
include neoadjuvant treatment, yet this variable was not
even evaluated in the primary regression analysis. Whether
neoadjuvant treatment has an influence on perioperative
mortality and morbidity is unclear. A number of studies did
not detect higher operative mortality.25–27 A meta-analysis
of randomized controlled trials showed a trend toward
higher operative mortality in pretreated patients (odds ratio
of 1.72; 0.96, 3.07 95% confidence interval, p=0.07).28
The Rotterdam study demonstrated a significant influence
for neoadjuvant treatment, chemotherapy alone, or radio-
chemotherapy. The Munich score includes only comorbid-
ity and performance status of the patient. As this score was
developed 1998, before the era of wide application of
neoadjuvant treatment, it may be outdated by now. This is
reflected by the poor predictive value in all cohorts,
including the pooled data. ASA score, the simplest and
oldest of the four validated scores, had no correlation to the
other scores at all.
The most surprising finding of this validation study is
that the two most recently developed scores, Philadelphia
and Rotterdam, had different predictive values for operative
mortality in the two country cohorts. Both scores were
excellent outcome predictors for the Swiss cohort but not
for the Australian cohort. This suggests that these scores
cannot be reliably applied to all centers undertaking
esophageal cancer surgery.
The difference in predictive value might be explained by
differences in perioperative management, differences in the
medical systems, and the fact that all Swiss patients were
operated in a single institution whereas the Australian
patients were operated in two university hospitals and two
private hospitals, albeit by members of the same surgical
group. The basic surgical approaches and postoperative
management guidelines in these two cohorts were similar.
In contrast to the Australian medical system, where a
number of consultant surgeons work in different public and
private institutions, the Swiss system has full-time consul-
tant surgeons in one institution only. This might result in
more tightly supervised postoperative management. Hospi-
tal and surgeon volume has been shown to influence
outcome.15,29–31 In our study, all hospitals met previous
definitions of high-volume centers.
The patients in the Swiss cohort were collected over a
time period of 17 years compared to 8 years in the Australian
cohort. This might have influenced the results. However, the
number of surgeons performing esophagectomies in the
Swiss cohort was stable during that period and all procedures
were supervised by the same head of department.
The Munich score had no significant predictive value
and poor goodness of fit for operative mortality in both
cohorts as well as in the pooled data. The main difference
between the Philadelphia and Rotterdam scores and the one
from Munich is the variety of variables used. The Munich
score concentrates on comorbidity and general performance
status whereas the two other scores include variables such
as age, neoadjuvant treatment, and hospital volume. The
range of variables having an impact on hospital mortality
discussed in the literature is very wide and to some extent
controversial. Age, sex, race, hospital volume, neoadjuvant
treatment, comorbidity, cancer stage, smoking, pulmonary
function (FEV 1, FVC), blood loss, and localization of the
tumor have all been shown to significantly influence
hospital death.1,4,11–15,17,18 This diversity of possible factors
might render it difficult to develop a uniformly applicable
score.
The development of risk prediction models in esopha-
geal surgery is important for two reasons: it allows
improvement of outcome by appropriate selection of
patients for surgery and it enables auditing results in
comparison to other institutions, countries, and published
series. The ideal prediction score should be simple to apply,
and it should reproducible across different institutions and
patient cohorts. This generalization has not yet been
achieved with these four scores
Conclusion
The results of this study show that none of the scores can be
applied generally to all institutions undertaking esophagec-
tomy and that a better overall predictive score or specific
prediction scores for each country might need to be
developed.
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